Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.62 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741668 | 0.86 | ESR1 (0.64) | ESR1ESR2MCHR1LTA4H | |
| SCHEMBL7936761 | 0.84 | ESR1 (0.62) | ESR1ESR2MCHR1LTA4H | |
| Hydrochloric Acid SCHEMBL224473 | 0.84 | ESR1 (0.62) | ESR1ESR2MCHR1LTA4H | |
| SCHEMBL10794866 | 0.83 | ABCB1 (0.64) | ESR1ESR2MCHR1LTA4H | |
| SCHEMBL3018123 | 0.82 | PARP10 (0.62) | ESR1ESR2PARP10LTA4HHRH3 | |
| SCHEMBL6812378 | 0.79 | EBP (0.67) | ESR1ESR2PARP10MCHR1LTA4H | |
| SCHEMBL11722280 | 0.79 | ESR1 (0.53) | ESR1ESR2MCHR1LTA4H | |
| SCHEMBL9637572 | 0.79 | MAPK1 (0.73) | PARP10 | |
| SCHEMBL6802602 | 0.78 | LTA4H (0.61) | ESR1ESR2MCHR1LTA4H | |
| Hydrochloric Acid SCHEMBL15876453 | 0.78 | ESR1 (0.55) | ESR1ESR2MCHR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | claimed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | claimed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | claimed |
| EP-4642766-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024145585-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | ESR1 368/4885ESR2 395/4885PARP10 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.